Abstract
A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have